EA202190088A1 - СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1 - Google Patents
СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1Info
- Publication number
- EA202190088A1 EA202190088A1 EA202190088A EA202190088A EA202190088A1 EA 202190088 A1 EA202190088 A1 EA 202190088A1 EA 202190088 A EA202190088 A EA 202190088A EA 202190088 A EA202190088 A EA 202190088A EA 202190088 A1 EA202190088 A1 EA 202190088A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies against
- methods
- cd3xmuc16
- treatment
- new policy
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000003211 malignant effect Effects 0.000 title 1
- 102000007269 CA-125 Antigen Human genes 0.000 abstract 2
- 108010008629 CA-125 Antigen Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 108091007744 Programmed cell death receptors Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение обеспечивает способы лечения, уменьшения степени тяжести или подавления роста злокачественного новообразования (например, рака яичников или рака поджелудочной железы). Способы по настоящему изобретению включают введение субъекту, нуждающемуся в этом, терапевтически эффективного количества антитела или его антигенсвязывающего фрагмента, которое специфически связывается с рецептором запрограммированной клеточной гибели 1 (PD-1), в комбинации с терапевтически эффективным количеством биспецифического антитела, которое специфически связывает муцин 16 (MUC16) и CD3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688251P | 2018-06-21 | 2018-06-21 | |
| PCT/US2019/038163 WO2019246356A1 (en) | 2018-06-21 | 2019-06-20 | Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190088A1 true EA202190088A1 (ru) | 2021-03-22 |
Family
ID=67254001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190088A EA202190088A1 (ru) | 2018-06-21 | 2019-06-20 | СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11254752B2 (ru) |
| EP (2) | EP3810281B1 (ru) |
| JP (1) | JP7403480B2 (ru) |
| KR (1) | KR20210023981A (ru) |
| CN (1) | CN112312970B (ru) |
| AU (1) | AU2019290170A1 (ru) |
| BR (1) | BR112020025476A2 (ru) |
| CA (1) | CA3103887A1 (ru) |
| CL (1) | CL2020003256A1 (ru) |
| DK (1) | DK3810281T3 (ru) |
| EA (1) | EA202190088A1 (ru) |
| ES (1) | ES2984972T3 (ru) |
| FI (1) | FI3810281T3 (ru) |
| HU (1) | HUE067985T2 (ru) |
| IL (1) | IL279251A (ru) |
| MA (2) | MA52962B1 (ru) |
| MX (1) | MX2020013905A (ru) |
| PH (1) | PH12020552115A1 (ru) |
| PL (1) | PL3810281T3 (ru) |
| PT (1) | PT3810281T (ru) |
| RS (1) | RS65886B1 (ru) |
| SG (1) | SG11202012137UA (ru) |
| TW (1) | TW202504917A (ru) |
| WO (1) | WO2019246356A1 (ru) |
| ZA (1) | ZA202007599B (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| ES2846748T3 (es) | 2015-03-30 | 2021-07-29 | Regeneron Pharma | Regiones constantes de cadenas pesadas con unión reducida a receptores Fc gamma |
| HRP20250234T1 (hr) | 2018-08-31 | 2025-04-11 | Regeneron Pharmaceuticals, Inc. | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitijela |
| CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
| WO2022197907A2 (en) * | 2021-03-18 | 2022-09-22 | Memorial Sloan-Kettering Cancer Center | Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors |
| WO2023033022A1 (ja) | 2021-08-31 | 2023-03-09 | 日本メジフィジックス株式会社 | 脱グリコシル化抗体の放射性複合体、及び、放射性医薬 |
| CN118475618A (zh) * | 2021-11-24 | 2024-08-09 | 瑞泽恩制药公司 | 用双特异性抗CD3xMUC16抗体和抗CTLA-4抗体治疗癌症的方法 |
| US20230312718A1 (en) * | 2022-01-07 | 2023-10-05 | Regeneron Pharmaceuticals, Inc | Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies |
| TW202334234A (zh) | 2022-01-10 | 2023-09-01 | 大陸商南京維立志博生物科技有限公司 | 一種抗體及其用途 |
| EP4494655A1 (en) * | 2022-03-16 | 2025-01-22 | Daiichi Sankyo Company, Limited | Combination of multi-specific molecule and immune checkpoint inhibitor |
| JP2025512377A (ja) | 2022-04-11 | 2025-04-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ユニバーサルな腫瘍細胞殺傷のための組成物及び方法 |
| WO2024173830A2 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| MXPA02001877A (es) | 1999-08-23 | 2002-08-20 | Dana Farber Cancer Inst Inc | Pd-1, un receptor para b7-4, y usos del mismo. |
| EP1576014B1 (en) | 2002-12-23 | 2011-06-29 | Wyeth LLC | Antibodies against pd-1 and uses thereof |
| CN103059138B (zh) | 2005-05-09 | 2015-10-28 | 小野药品工业株式会社 | 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| MX342623B (es) | 2009-06-26 | 2016-10-06 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| EP2734551B1 (en) | 2011-07-24 | 2018-01-10 | Cure Tech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| US20180355038A1 (en) | 2015-09-23 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| FI3394103T3 (fi) * | 2015-12-22 | 2023-08-30 | Regeneron Pharma | Anti-PD-1-vasta-aineiden ja bispesifisten anti-CD20-/anti-CD3-vasta-aineiden yhdistelmä syövän hoitoon |
| TWI822521B (zh) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| SMT202200359T1 (it) | 2016-09-23 | 2022-11-18 | Regeneron Pharma | Anticorpi anti-muc16 (mucina 16) |
| CA3040504A1 (en) * | 2016-10-14 | 2018-04-19 | Xencor, Inc. | Il15/il15ra heterodimeric fc-fusion proteins |
| BR112019010878A2 (pt) | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
-
2019
- 2019-06-19 TW TW113114645A patent/TW202504917A/zh unknown
- 2019-06-20 MA MA52962A patent/MA52962B1/fr unknown
- 2019-06-20 MX MX2020013905A patent/MX2020013905A/es unknown
- 2019-06-20 WO PCT/US2019/038163 patent/WO2019246356A1/en active IP Right Grant
- 2019-06-20 FI FIEP19739472.9T patent/FI3810281T3/fi active
- 2019-06-20 HU HUE19739472A patent/HUE067985T2/hu unknown
- 2019-06-20 DK DK19739472.9T patent/DK3810281T3/da active
- 2019-06-20 PT PT197394729T patent/PT3810281T/pt unknown
- 2019-06-20 EA EA202190088A patent/EA202190088A1/ru unknown
- 2019-06-20 KR KR1020217000649A patent/KR20210023981A/ko active Pending
- 2019-06-20 MA MA71708A patent/MA71708A/fr unknown
- 2019-06-20 RS RS20240959A patent/RS65886B1/sr unknown
- 2019-06-20 CN CN201980040564.9A patent/CN112312970B/zh active Active
- 2019-06-20 AU AU2019290170A patent/AU2019290170A1/en active Pending
- 2019-06-20 EP EP19739472.9A patent/EP3810281B1/en active Active
- 2019-06-20 CA CA3103887A patent/CA3103887A1/en active Pending
- 2019-06-20 BR BR112020025476-2A patent/BR112020025476A2/pt unknown
- 2019-06-20 ES ES19739472T patent/ES2984972T3/es active Active
- 2019-06-20 JP JP2020570938A patent/JP7403480B2/ja active Active
- 2019-06-20 US US16/447,067 patent/US11254752B2/en active Active
- 2019-06-20 PL PL19739472.9T patent/PL3810281T3/pl unknown
- 2019-06-20 EP EP24176671.6A patent/EP4424712A3/en active Pending
- 2019-06-20 SG SG11202012137UA patent/SG11202012137UA/en unknown
-
2020
- 2020-12-07 IL IL279251A patent/IL279251A/en unknown
- 2020-12-07 ZA ZA2020/07599A patent/ZA202007599B/en unknown
- 2020-12-10 PH PH12020552115A patent/PH12020552115A1/en unknown
- 2020-12-16 CL CL2020003256A patent/CL2020003256A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020013905A (es) | 2021-03-09 |
| ES2984972T3 (es) | 2024-10-31 |
| TW202504917A (zh) | 2025-02-01 |
| EP4424712A3 (en) | 2024-11-13 |
| MA52962A (fr) | 2021-04-28 |
| PH12020552115A1 (en) | 2021-08-02 |
| SG11202012137UA (en) | 2021-01-28 |
| TW202005985A (zh) | 2020-02-01 |
| KR20210023981A (ko) | 2021-03-04 |
| CN112312970A (zh) | 2021-02-02 |
| ZA202007599B (en) | 2025-02-26 |
| CL2020003256A1 (es) | 2021-04-30 |
| EP3810281B1 (en) | 2024-07-24 |
| IL279251A (en) | 2021-01-31 |
| PL3810281T3 (pl) | 2024-11-04 |
| JP2021528423A (ja) | 2021-10-21 |
| BR112020025476A2 (pt) | 2021-03-16 |
| HUE067985T2 (hu) | 2024-12-28 |
| US11254752B2 (en) | 2022-02-22 |
| CN112312970B (zh) | 2025-05-23 |
| EP4424712A2 (en) | 2024-09-04 |
| FI3810281T3 (fi) | 2024-08-14 |
| MA71708A (fr) | 2025-05-30 |
| RS65886B1 (sr) | 2024-09-30 |
| EP3810281A1 (en) | 2021-04-28 |
| CA3103887A1 (en) | 2019-12-26 |
| US20190389966A1 (en) | 2019-12-26 |
| PT3810281T (pt) | 2024-08-02 |
| JP7403480B2 (ja) | 2023-12-22 |
| DK3810281T3 (da) | 2024-08-19 |
| AU2019290170A1 (en) | 2021-01-07 |
| MA52962B1 (fr) | 2024-10-31 |
| WO2019246356A1 (en) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190088A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ БИСПЕЦИФИЧЕСКИМИ АНТИТЕЛАМИ ПРОТИВ CD3xMUC16 И АНТИТЕЛАМИ ПРОТИВ PD-1 | |
| EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
| BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
| PH12020552221A1 (en) | Anti-pd-1 antibodies and uses thereof | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
| MX2019009772A (es) | Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon. | |
| MX2019013033A (es) | Formulaciones estables de anticuerpos anti-tigit solos y en combinacion con anticuerpos anti-receptor de muerte programada 1 (pd-1) y metodos para su uso. | |
| EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| EA202092420A1 (ru) | Антитело против pd-l1 и его применение | |
| EA201990374A1 (ru) | Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
| MX2020002301A (es) | Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico. | |
| MX2025001239A (es) | Métodos para tratar cáncer de próstata resistente a la castración metastasico con anticuerpos biespecíficos anti-psma x anti-cd28 en combinación con anticuerpos anti-pd-1 | |
| BR112021020532A2 (pt) | Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3 | |
| MX2023006777A (es) | Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). | |
| MX2024008055A (es) | Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1. | |
| PH12020551451A1 (en) | Anti-cd25 for tumour specific cell depletion | |
| MX2021012765A (es) | Metodos para tratar el cancer renal con un anticuerpo anti-psma/cd3. | |
| MX2020013450A (es) | Materiales y métodos para tratar el cancer y los trastornos relacionados con el estrés. | |
| MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
| MX2024006187A (es) | Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4. |